Guggenheim Reaffirms “Buy” Rating for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ:NBIX)‘s stock had its “buy” rating reissued by analysts at Guggenheim in a note issued to investors on Wednesday,Benzinga reports. They currently have a $175.00 price objective on the stock. Guggenheim’s price target indicates a potential upside of 16.99% from the stock’s previous close.

Several other research analysts also recently commented on NBIX. Piper Sandler boosted their price objective on shares of Neurocrine Biosciences from $190.00 to $207.00 and gave the company an “overweight” rating in a research report on Wednesday. UBS Group decreased their price target on Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. BMO Capital Markets lowered their price target on Neurocrine Biosciences from $147.00 to $140.00 and set a “market perform” rating for the company in a report on Thursday, February 12th. Citigroup upped their price objective on Neurocrine Biosciences from $204.00 to $242.00 and gave the stock a “buy” rating in a research report on Tuesday, April 7th. Finally, Wall Street Zen raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 25th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $183.75.

Neurocrine Biosciences Stock Up 1.7%

NBIX opened at $149.59 on Wednesday. The stock has a market capitalization of $15.04 billion, a price-to-earnings ratio of 23.05, a P/E/G ratio of 0.74 and a beta of 0.34. Neurocrine Biosciences has a twelve month low of $115.66 and a twelve month high of $160.18. The company has a 50-day simple moving average of $131.12 and a 200 day simple moving average of $137.85.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Wednesday, February 11th. The company reported $1.88 EPS for the quarter, missing the consensus estimate of $2.36 by ($0.48). Neurocrine Biosciences had a net margin of 21.55% and a return on equity of 19.79%. The firm had revenue of $805.50 million during the quarter, compared to the consensus estimate of $804.21 million. During the same period in the prior year, the business earned $1.69 earnings per share. Neurocrine Biosciences’s quarterly revenue was up 28.3% compared to the same quarter last year. Sell-side analysts anticipate that Neurocrine Biosciences will post 6.57 EPS for the current fiscal year.

Hedge Funds Weigh In On Neurocrine Biosciences

Several large investors have recently bought and sold shares of NBIX. USA Financial Formulas bought a new stake in shares of Neurocrine Biosciences during the fourth quarter worth about $25,000. Geneos Wealth Management Inc. raised its holdings in Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after buying an additional 135 shares during the last quarter. Golden State Wealth Management LLC raised its holdings in Neurocrine Biosciences by 120.5% in the 3rd quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock valued at $26,000 after buying an additional 100 shares during the last quarter. Eastern Bank acquired a new stake in Neurocrine Biosciences during the 3rd quarter worth approximately $27,000. Finally, DJE Kapital AG acquired a new stake in Neurocrine Biosciences during the 4th quarter worth approximately $28,000. 92.59% of the stock is currently owned by institutional investors.

Key Headlines Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Multiple firms boosted price targets and ratings (Citigroup, Piper Sandler, Morgan Stanley, RBC, Wedbush, Guggenheim, Truist), signaling stronger analyst conviction and creating upward pressure on the stock. Morgan Stanley PT raise Piper Sandler outlook Additional coverage
• Positive Sentiment: Q1 2026 results and commentary were well received: INGREZZA sales came in stronger than expected and the company reported a record quarter, which supports near?term revenue growth expectations. Earnings coverage
• Positive Sentiment: Commercial adoption support for CRENESSITY improved after publication of peer?reviewed expert recommendations that guide glucocorticoid dose reduction—this lowers a practical barrier for clinicians and could accelerate uptake. CRENESSITY publication
• Positive Sentiment: Analyst commentary and thematic coverage highlighting NBIX as a growth story (Zacks) add to the narrative that the company can sustain above?average financial growth. Zacks growth thesis
• Neutral Sentiment: Strategic items such as the Soleno deal were framed as “risky upside” — potential high reward but with execution and integration risk, which could add volatility. Soleno deal analysis
• Neutral Sentiment: Some commentary questions whether recent gains have already priced in caution or optimism, suggesting upside depends on continued execution and guidance. Valuation commentary

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research?driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.